Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Clinical Summary

Prostate Cancer: Screening

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Clinical Summary of U.S. Preventive Services Task Force Recommendation

Population Adult males
Recommendation Do not use prostate-specific antigen (PSA)–based screening for prostate cancer.
Grade: D
Screening Tests Contemporary recommendations for prostate cancer screening all incorporate the measurement of serum PSA levels; other methods of detection, such as digital rectal examination or ultrasonography, may be included.

There is convincing evidence that PSA-based screening programs result in the detection of many cases of asymptomatic prostate cancer, and that a substantial percentage of men who have asymptomatic cancer detected by PSA screening have a tumor that either will not progress or will progress so slowly that it would have remained asymptomatic for the man's lifetime (i.e., PSA-based screening results in considerable overdiagnosis).

Interventions Management strategies for localized prostate cancer include watchful waiting, active surveillance, surgery, and radiation therapy.

There is no consensus regarding optimal treatment.

Balance of harms and benefits The reduction in prostate cancer mortality 10 to 14 years after PSA-based screening is, at most, very small, even for men in the optimal age range of 55 to 69 years.

The harms of screening include pain, fever, bleeding, infection, and transient urinary difficulties associated with prostate biopsy, psychological harm of false-positive test results, and overdiagnosis.

Harms of treatment include erectile dysfunction, urinary incontinence, bowel dysfunction, and a small risk for premature death.

Because of the current inability to reliably distinguish tumors that will remain indolent from those destined to be lethal, many men are being subjected to the harms of treatment for prostate cancer that will never become symptomatic.

The benefits of PSA-based screening for prostate cancer do not outweigh the harms.

Relevant USPSTF Recommendations Recommendations on screening for other types of cancer can be found at http://www.uspreventiveservicestaskforce.org.

For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org.

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Current as of: May 2012

Internet Citation: Clinical Summary: Prostate Cancer: Screening. U.S. Preventive Services Task Force. March 2017.
https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/prostate-cancer-screening

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857